Zogenix, Inc (NASDAQ:ZGNX) CEO Roger Hawley unloaded 25,078 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $2.10, for a total transaction of $52,663.80. Following the completion of the sale, the chief executive officer now directly owns 1,204,447 shares in the company, valued at approximately $2,529,339. Zogenix, Inc. (NASDAQ:ZGNX) stock performance was -0.54% in last session and finished the day at $1.84. Traded volume was 5.05million shares in the last session and the average volume of the stock remained 3.04million shares. The beta of the stock remained 2.12. Zogenix, Inc. (NASDAQ:ZGNX) insider ownership is 0.90%.

The FDA will decide on Wednesday whether to approve a new weight loss drug, Contrave, from Orexigen Therapeutics Inc. (NASDAQ:OREX), a smallish biotech company with a market cap of just $760 million. Orexigen Therapeutics, Inc. (NASDAQ:OREX) rose 3.07 percent to $6.71 Monday on volume of 6.52million shares. The intra-day range of the stock was $6.51 to $6.78. Orexigen Therapeutics, Inc. (NASDAQ:OREX) has a market capitalization of $780.56million.

Merck & Co. Inc. (NYSE:MRK) made an official statement, revealing that it reached an agreement for the acquisition of Idenix Pharmaceuticals Inc. in a deal that is estimated to 3.85 billion dollars. The purchase will help the company to broaden its experimental pipeline for hepatitis C treatments. Merck & Co., Inc. (NYSE:MRK)’s stock on June 09, 2014 reported a increase of 0.16% to the closing price of $57.94. Its fifty two weeks range is $44.62 -$59.84. The total market capitalization recorded $169.74billion. The overall volume in the last trading session was 8.08million shares. In its share capital, MRK has 2.92billion outstanding shares.

Boston Scientific Corporation (NYSE:BSX) has launched the RESPOND Post Market Registry to evaluate the real world performance of the Lotus Valve System – a differentiated second generation transcatheter aortic valve implantation (:TAVI) technology. On Monday, shares of Boston Scientific Corporation (NYSE:BSX) dropped -2.82% to close the day at $12.76. Company return on investment (ROI) is 2.10% and its monthly performance is recorded as -0.31%. Boston Scientific Corporation (NYSE:BSX) quarterly revenue growth is -5.20%.

Bristol-Myers Squibb Co. (NYSE:BMY) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most “interesting” ideas that merit further research by investors. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was -1.40% in last session and finished the day at $46.59. Traded volume was 11.93million shares in the last session and the average volume of the stock remained 8.82million shares. The beta of the stock remained 0.48. Bristol-Myers Squibb Co (NYSE:BMY) insider ownership is 0.10%.